DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/gbr5bg/north_america) has announced the addition of the “North America Ophthalmology Cataract Surgery Devices Market by Sub-Market (Intraocular Lenses, Phacoemuls…
Uncategorized
CyPass lowers IOP, avoids need for conventional glaucoma surgery
Implantation of a supraciliary micro-stent may cause fewer complications, lower IOP and reduce medication dependence compared with conventional glaucoma surgery in open-angle glaucoma patients, according to a study.The multicenter, single-arm intervent…
Smartphone App Identifies Eye Conditions, Directs Patients to Specialists
A team at Mexico’s Medical and Surgical Center for Retina, a small firm of about a dozen people, has created a smartphone software that can help general medical practitioners spot eye conditions that currently require a specialist to diagnose. The app is not intended to replace ophthalmologists, but was designed instead to help direct pa (Read more...)
Uncategorized
Santen files investigational new drug application for DE-122 for wet AMD treatment
Santen Pharmaceutical has filed an investigational new drug application with the FDA to begin clinical studies of DE-122 in patients with wet age-related macular degeneration, according to a press release from Tracon Pharmaceuticals. DE-122 is the ophthalmic formulation of TRC105, Tracon’s anti-endoglin antibody. Santen licensed the global rights from Tracon for the development of TRC105 in March 2014. Under the terms of the agreement, the filing will trigger a $3 million milestone payment to Tracon, the release said.
Uncategorized
OSLI Retina: Endoscopy remains a valuable tool for vitreoretinal surgery
For this column, Dr. Goldberg from Walnut Creek, Calif., was asked to comment on the role of endoscopy, a newer and less commonly available device, in vitreoretinal surgery.Modern-day vitreoretinal specialists are bombarded with new equipment, instrumentation, and pharmaceuticals at a rate never seen before. It is our community’s responsibility to evaluate and educate each other on the precise role of these emerging technologies. With open and productive community discussion, we can teach each other when certain agents and technologies should be used to optimize the risk-benefit ratio.
Uncategorized
pSivida Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur™ for Uveitis to Be Reported Next Week
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida announces top-line results from investigator-sponsored phase II study of Medidur for uveitis to be reported next week at ASRS Meeting in Vienna